Э.Баярмаа
Loading...
Товч нэр
Э.Баярмаа
Бүтэн нэр
Энхбат Баярмаа
Латин нэр
Enkhbat Bayarmaa
Албан тушаал
Тэнхимийн эрхлэгч
Эрдмийн цол
Профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Clinical Features of Hepatitis B and C Virus-Related Hepatocellular Carcinoma(Mongolian National University of Medical Sciences, 2022-09-30); ;Erdenebileg Taivanbaatar; ; Objective: To compare the clinical characteristics of hepatitis B virus-related hepatocellular carcinoma (HBV group) and C virus-related hepatocellular carcinoma (HCV group). Methods: By a single century, we analyzed the clinical characteristics of 23 patients with hepatitis B virus-related hepatocellular carcinoma (HBV group) and 34 with hepatitis C virus-related hepatocellular carcinoma (HCV group). Results: The patients in the HBV group (mean age 61.1 year) were about 6 years younger than those in the HCV group (mean age 67.1 year). Liver function, as measured by indocyanine green retention at 15 min, was better in the HBV group (17.5 %) than in the HCV group (25.4 %). A higher proportion of the HBV group (55 %) than the HCV group (44 %) had clinical stage I. T-factor differed significantly between the groups: 53 % of the HBV group were T3 - 4 compared with 41 % of the HCV group. Furthermore, a higher proportion of the HBV group was graded 2 - 3 for tumor thrombus in the portal vein (20.3 %) and had poorly differentiated hepatocellular carcinoma (7 %) compared with the HCV group (7.1 % and 5 % respectively). Univariate analysis identified poor prognostic factors for hepatocellular carcinoma as HBV, age < or = 50 year, clinical stage II-III, a high AFP level, higher number of tumors, larger tumor size, tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3. On multivariate analysis, poor prognostic factors were a high AFP level, a higher number of tumors, and tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3, but not HBV, age, clinical stage, or tumor size. In the multiple logistic regression models on the hepatitis infection, the OR for ASAT was 2.01 (95 % CI 1.41 - 6.91), statistically significant (p < 0.05). Conclusion: These results suggest that HBV itself is not a stronger prognostic factor than HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of tumor mutational burden and immune infiltration on cervical squamous cell carcinoma prognosis(2026-08-26); ; ;Shutao Tan ;Zhenyong YangYunfeng DaiIntroduction: Cervical squamous cell carcinoma (CESC) remains a significant global health challenge for women, necessitating the discovery of precise molecular biomarkers to optimize personalized treatment and immunotherapy strategies. Objective: Leveraging bioinformatics data from The Cancer Genome Atlas (TCGA) and the independent CGCI–HTMCP–CC cohort for external validation, this study rigorously evaluated the prognostic role of tumor mutational burden (TMB) in CESC. Methods: Our methodology utilized standardized transcripts per million (TPM) normalization and the maximally selected rank statistics (maxstat) algorithm to establish biologically optimal TMB thresholds, moving beyond traditional median-based stratification. Results: While somatic mutation analysis identified high frequencies in TTN (29%) and PIK3CA (27%), high TMB levels did not directly correlate with patient overall survival (p = 0.720). However, a marginal non-significant trend was observed between elevated TMB and advanced tumor T-staging (p = 0.057). Differential expression and Cox regression analyses highlighted PTGS2 as a distinctive TMB-related risk gene. Based on this, a TMB-related risk score (TMBRS) was constructed, demonstrating moderate yet consistent predictive utility (area under the curve = 0.696) across both primary and independent validation cohorts. Detailed immune profiling via Cell-type Identification by Estimating Relative Subsets of RNA Transcripts and Tumor Immune Estimation Resource revealed that high TMB and lower risk scores are specifically associated with increased infiltration of CD8+ T cells and M1 macrophages, suggesting enhanced local immune recognition. Conclusion: Although the clinical utility of the TMBRS is currently moderate, this research provides a critical proof of concept for the interplay among PTGS2, mutational load, and the tumor microenvironment, offering valuable mechanistic insights for future large-scale prospective clinical trials.
